Page 268 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 268
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0851 EFFECTIVENESS OF SOFOSBUVIR AND RIBAVIRIN FOR
GENOTYPE 2 AND 3 HCV AMONG NON-CIRRHOTIC,
CIRRHOTIC, AND POST-TRANSPLANT PATIENTS AT 3 US
MEDICAL CENTERS
Michael Leise*, Benjamin Rodriguez, Surakit Pungpapong, Bashar Aqel,
Amy Chervenak, Tuesday Werner, Jennifer Murphy, Tanisha M. Henry,
Kristen Ryland, Andrew Keaveny, Hugo Vargas, Kymberly Watt,
The United States
P0852 CLINICAL CHARACTERISTICS AND OUTCOMES OF
CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH
NEWER DIRECT-ACTING ANTIVIRAL (DAA)-BASED
REGIMENS FROM A LARGE US PAYER PERSPECTIVE
Neeta Tandon*, Jamie Forlenza, Alyssa Goolsby Hunter,
Stephanie D. Korrer, Ami Buikema, The United States
P0853 SERUM CYSTATIN C AND NGAL LEVELS AT THE
OUTSET OF PROTEASE INHIBITOR ANTIVIRAL
ePOSTERS THERAPY POSITIVELY PREDICT RENAL DYSFUNCTION
DEVELOPMENT AND ANAEMIA SEVERITY
Suman Verma*, Ivana Kraslova, Kosh Agarwal, The United Kingdom
P0854 ESTIMATING THE COST OFFSETS AND IMPACT ON
QUALITY-ADJUSTED LIFE EXPECTANCY ASSOCIATED
WITH INCREASING SVR IN UK PATIENTS WITH HEPATITIS
C-RELATED ADVANCED LIVER DISEASE
Thomas Ward*, Phil McEwan, Samantha Webster, Daniel Sugrue,
Yong Yuan, Anupama Kalsekar, The United Kingdom
P0855 PHARMACOKINETICS OF ABT-493 AND ABT-530 IS SIMILAR
IN HEALTHY CAUCASIAN, CHINESE, AND JAPANESE
ADULT SUBJECTS
Tianli Wang*, Wei Liu, Armen Asatryan, Jingtao Wu, Andrew Campbell,
Jens Kort, Sandeep Dutta, The United States
P0856 OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR
WITH RIBAVIRIN (RBV) HAS MILD IMPACT ON HEALTH-
RELATED QUALITY OF LIFE (HRQOL) COMPARED WITH
PLACEBO DURING 12-WEEK TREATMENT IN TREATMENT-
EXPERIENCED ADULTS WITH CHRONIC HEPATITIS C
(CHC)
Yan Liu*, Lois Larsen, Marc Bourliere, Robert Baran, Timothy Juday,
The United States
268 The International Liver Congress™ 2015 • ILC Programme
P0851 EFFECTIVENESS OF SOFOSBUVIR AND RIBAVIRIN FOR
GENOTYPE 2 AND 3 HCV AMONG NON-CIRRHOTIC,
CIRRHOTIC, AND POST-TRANSPLANT PATIENTS AT 3 US
MEDICAL CENTERS
Michael Leise*, Benjamin Rodriguez, Surakit Pungpapong, Bashar Aqel,
Amy Chervenak, Tuesday Werner, Jennifer Murphy, Tanisha M. Henry,
Kristen Ryland, Andrew Keaveny, Hugo Vargas, Kymberly Watt,
The United States
P0852 CLINICAL CHARACTERISTICS AND OUTCOMES OF
CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH
NEWER DIRECT-ACTING ANTIVIRAL (DAA)-BASED
REGIMENS FROM A LARGE US PAYER PERSPECTIVE
Neeta Tandon*, Jamie Forlenza, Alyssa Goolsby Hunter,
Stephanie D. Korrer, Ami Buikema, The United States
P0853 SERUM CYSTATIN C AND NGAL LEVELS AT THE
OUTSET OF PROTEASE INHIBITOR ANTIVIRAL
ePOSTERS THERAPY POSITIVELY PREDICT RENAL DYSFUNCTION
DEVELOPMENT AND ANAEMIA SEVERITY
Suman Verma*, Ivana Kraslova, Kosh Agarwal, The United Kingdom
P0854 ESTIMATING THE COST OFFSETS AND IMPACT ON
QUALITY-ADJUSTED LIFE EXPECTANCY ASSOCIATED
WITH INCREASING SVR IN UK PATIENTS WITH HEPATITIS
C-RELATED ADVANCED LIVER DISEASE
Thomas Ward*, Phil McEwan, Samantha Webster, Daniel Sugrue,
Yong Yuan, Anupama Kalsekar, The United Kingdom
P0855 PHARMACOKINETICS OF ABT-493 AND ABT-530 IS SIMILAR
IN HEALTHY CAUCASIAN, CHINESE, AND JAPANESE
ADULT SUBJECTS
Tianli Wang*, Wei Liu, Armen Asatryan, Jingtao Wu, Andrew Campbell,
Jens Kort, Sandeep Dutta, The United States
P0856 OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR
WITH RIBAVIRIN (RBV) HAS MILD IMPACT ON HEALTH-
RELATED QUALITY OF LIFE (HRQOL) COMPARED WITH
PLACEBO DURING 12-WEEK TREATMENT IN TREATMENT-
EXPERIENCED ADULTS WITH CHRONIC HEPATITIS C
(CHC)
Yan Liu*, Lois Larsen, Marc Bourliere, Robert Baran, Timothy Juday,
The United States
268 The International Liver Congress™ 2015 • ILC Programme
